Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

Shore, Neal D.; Oliver, Louisa; Shui, Irene M.; Gayle, Alicia; Wong, On-Ye; Kim, Jeri; Payne, Sarah; Amin, Suvina; Ghate, Sameer

doi:10.1097/ju.0000000000001570

Cited by 15 publications

(10 citation statements)

References 36 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, reviews of the literature concluded that the DDR gene with the highest prevalence of germline mutation was BRCA2 in those patients. 24,25 Only, Darst et al 21 reported a frequency of BRCA2 mutation that wasn't the highest one, but this study included Finnish patients who carried no BRCA2 mutation. This is in agreement with previous results from Ikonen et al 26 who screened 444 unselected PC patients for six BRCA2 recurrent germline mutations in Finland, and found no mutation.…”

Section: Discussionmentioning

confidence: 97%

DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries

Abdi

Basset²,

Perrot

et al. 2022

The Prostate

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

Section: Discussionmentioning

confidence: 97%

DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries

Abdi

Basset²,

Perrot

et al. 2022

The Prostate

View full text Add to dashboard Cite

show abstract

“…Further, the consistency of our results with the results of previously published studies provides confidence in our analysis and results. The use of ARTA alone may have limited efficacy in patients with prostate cancer who had disease progression and is generally not recommended by clinical experts and RADAR II guidelines [ 26 , 27 ]. Yet, it was a very common regimen used in this population (43% in McKay et al) [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents

et al. 2022

View full text Add to dashboard Cite

Introduction The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to evolve. Sipuleucel-T was the first immunotherapy approved by the US Food and Drug Administration (FDA) to treat asymptomatic or minimally symptomatic mCRPC. The androgen receptor-targeting agents (ARTAs) abiraterone acetate and enzalutamide were initially approved to treat mCRPC. Looking at chemotherapy-naïve men with mCRPC, we compared survival outcomes between the sipuleucel-T + ARTA cohort (men who received either sipuleucel-T or an ARTA in the first line, and then the other in the second line within 6 months) and the ARTA monotherapy cohort (men who only received ARTA monotherapy). Methods This retrospective cohort analysis used longitudinal, adjudicated claims data from the US Medicare Fee-for-Service 100% research identifiable dataset that includes both urologic and oncologic practice settings. Eligible men started their first mCRPC treatment with either sipuleucel-T or ARTA in either 2014 or 2015 and had continuous Medicare Parts A, B, and D eligibility for the subsequent 3 years. A multivariable Cox proportional hazards regression model was used to analyze overall survival (OS), both overall and by index year, and to control for differences. Results The sipuleucel-T + ARTA and ARTA monotherapy cohorts comprised 773 and 4642 men, respectively, with different characteristics at treatment start. The most commonly used ARTAs were enzalutamide in the former and abiraterone in the latter cohort. Median OS was 30.4 and 14.3 months in the sipuleucel-T + ARTA and ARTA monotherapy cohorts, respectively, with the sipuleucel-T + ARTA cohort having a 28.3% lower risk of death than the ARTA monotherapy cohort (hazard ratio 0.717; 95% CI 0.648, 0.793; p < 0.01). Conclusions This real-world study of mCRPC treatment indicates that men receiving sipuleucel-T and ARTAs had a longer median OS than patients receiving treatment with an ARTA alone, suggesting that leveraging mechanisms of action can be beneficial in treating patients with mCRPC. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02085-6.

show abstract

“…В «Журнале урологии» («Journal of Urology») в апреле 2021 г. опубликованы результаты систематического обзора литературы, посвященного этой проблеме. Обзор включал литературные данные с января 2009 г. по май 2019 г. для оценки глобальной эпидемиологии по метастатическому гормоночувствительному, неметастатическому гормонорезистентному и метастатическому гормонорезистентному раку предстательной железы [13].…”

Section: статистика и эпидемиологияunclassified

“…Распространенность мКРРПЖ оценивалась от 1,2 до 2,1% среди всех случаев рака простаты. Авторы уверяют, что реально опубликованное количество статей, посвященных этой проблеме, невелико [13]. Так, H. Scher и соавт.…”

Section: статистика и эпидемиологияunclassified

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Огнерубов¹

2021

J. Mod. Onco.

View full text Add to dashboard Cite

The incidence of prostate cancer in the structure of malignant neoplasms occupies the fourth place, it is 7.3%. 1 414 259 new cases and 375 304 deaths were estimated worldwide in 2020. In recent decades, there was a significant increase in the number of cases of metastatic castration-resistant prostate cancer (mCRPC). There is no consensus on the optimal treatment choice, nowadays. The various therapeutic options are offered for these aims. But, the regimes and the consistence of their application are problematical and far from being resolved. The aim of this review is to analyze the studies on the use of cabazitaxel in the treatment of mCRPC. The history of the taxanes application in advanced and metastatic prostate cancer dates back to 2004, when the United States Food and Drug Administration registered docetaxel as first-line therapy for patients with metastatic prostate cancer. Cabazitaxel the new second generation taxane appeared in 2010, and showed the activity in the development of castration resistance. The drug demonstrated high antitumor activity and significant efficacy at the time of progression against the background of treatment with docetaxel and androgen receptor inhibitors. The results of the number of the randomized clinical trials associated with the various aspects of treatment tactics in mCRPC are available for the analysis, nowadays. However, these data and especially the clinical benefit are ambiguous, and sometimes contradictory. The review presents the results of the scientific researches, international clinical studies concerning the various aspects of mCRPC, in particular the choice of modern optimal treatment tactics.

show abstract

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

Cited by 15 publications

References 36 publications

DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries

DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Contact Info

Product

Resources

About